Dr CHIU Ka Fung Peter    
趙家鋒

Associate Professor
MBChB (CUHK), FRCSEd (Urol), FCSHK, FHKAM (Surg)

Urology
(852) 3505 2625 / Appointment 3505 2954
peterchiuadd this for spam@add this for spamsurgery.cuhk.edu.hk
AAY-2052-2020
0000-0002-1499-8372

Biography

Dr Peter Chiu is currently an Associate Professor of the Chinese University of Hong Kong. He has primary interests in prostate cancer and benign prostatic hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities including blood biomarker prostate health index (phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion biopsy. He is the principal investigator of SMART trial, a multicentre randomized controlled trial in comparing MRI prostate pathway and extended transperineal prostate biopsy pathway in the diagnosis of significant prostate cancer. He is also leading a study on using biomarkers and MRI for prostate cancer screening in Hong Kong as part of the CUHK Jockey club multi-cancer screening program.

Dr Chiu was involved in the initiation of focal therapy service (HIFU and Cryotherapy) for prostate cancer in Hong Kong, and is the principal investigator of a phase 2 clinical trial on Targeted Microwave Ablation (TMA) for prostate cancer. For treatment of benign prostatic hyperplasia, he has conducted research in water vapour thermal therapy (REZUM), prostate artery embolization (PAE) and photoselective vaporization of prostate (PVP). He has received numerous research funding and has published more than 90 articles in peer-reviewed journals including European Urology, European Urology Oncology, Journal of Urology, BJU International, and Prostate Cancer and Prostatic diseases.

Dr Chiu is currently the President of the Hong Kong Urological Association (HKUA).

Research Interests

• Blood and urine biomarkers (prostate health index, urine Spermine risk score, etc) for prostate cancer
• Prostate cancer screening
• Transperineal MRI-Ultrasound fusion prostate biopsy
• Focal therapy for prostate cancer (Targeted Microwave Ablation [TMA], HIFU, Cryotherapy)
• Advanced robotic surgery for urological cancers
• Novel treatment for benign prostatic hyperplasia
• Microsurgery under advanced imaging for varicocele treatment

Additional Information

• President, Hong Kong Urological Association (since 2022)
• Member, The EAU Young Academic Urologists Prostate cancer working group
  https://uroweb.org/offices/yau-working-group-prostate-cancer
• Council member, uCARE research council in Societe Internationale D'Urologie (SIU)
• Editorial board member, International Journal of Urology
• Associate editor, Frontiers in Surgery (Genitourinary Surgery)
• Associate editor, Grand Rounds in Urology
  https://grandroundsinurology.com

Selected Publications

1. Chiu PK, Chan CH, Yee CH, Lau SY, Teoh JY, Wong HF, Lo KL, Yuen TY, Hung HY, Cho CC, Ng CF. Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. Prostate Cancer Prostatic Dis. 2022 Jul 14.
2. Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer Prostatic Dis. 2021 Aug 27.
3. Chiu PK, Fung YH, Teoh JY, Chan CH, Lo KL, Li KM, Tse RT, Leung CH, Wong YP, Roobol MJ, Wong KL, Ng CF. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):542-548.
4. Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study. Eur Urol Oncol. 2022 Apr 15:S2588-9311(22)00057-8.
5. Zhu Y, Wei Y, Zeng H, Li Y, Ng CF, Zhou F, He C, Sun G, Ni Y, Chiu PKF, Teoh JYC, Wang B, Pan J, Wan F, Dai B, Qin X, Lin G, Gan H, Wu J, Ye D. Inherited Mutations in Chinese Men With Prostate Cancer. J Natl Compr Canc Netw. 2021 Oct 15;20(1):54-62.
6. Chiu PK, Lo KL, Teoh JY, Ma SF, Leung CH, Wong HF, Li KM, Sae-Lo K, Kwok SW, Li SY, Yee CH, Hou SM, Ng CF. Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):431-438. doi: 10.1038/s41391-020-00293-1.
7. Castellani D, Pirola GM, Law YXT, Gubbiotti M, Giulioni C, Scarcella S, Wroclawski ML, Chan E, Chiu PK, Teoh JY, Gauhar V, Rubilotta E. Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. J Urol. 2022 Jan;207(1):25-34.
8. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2019 Apr;75(4):558-561.
9. Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2019 Feb;75(2):310-318.
10. Ng CF, Teoh JY, Chiu PK, Yee CH, Chan CK, Hou SS, Kaouk J, Chan ES. Robot-assisted single-port radical prostatectomy: A phase 1 clinical study. Int J Urol. 2019 Sep;26(9):878-883.
11. Chiu PK, Alberts AR, Venderbos LDF, Bangma CH, Roobol MJ. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2017 Sep;120(3):394-400.
12. Chiu PK, Roobol MJ, Nieboer D, Teoh JY, Yuen SK, Hou SM, Yiu MK, Ng CF. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):99-104.
13. Chiu PK, Teoh JY, Lee WM, Yee CH, Chan ES, Hou SM, Ng CF. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Investig Clin Urol. 2016 Sep;57(5):336-42.
14. Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM, Bangma CH, Ng CF. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol. 2016 Oct;48(10):1631-7.
15. Teoh JY, Chiu PK, Yee CH, Wong HM, Chan CK, Chan ES, Hou SS, Ng CF. Prostatic artery embolization in treating benign prostatic hyperplasia: a systematic review. Int Urol Nephrol. 2017 Feb;49(2):197-203.